Nanotechnology revolutionizing antimicrobial therapy for superbug infections
Source abstract
Abstract
Infectious diseases still pose one of the leading causes of morbidity and mortality in the world, and the problem of antimicrobial resistance is becoming more and more dangerous to the health of global populations. Multidrug-resistant (MDR) bacteria have emerged rapidly, and this has become a cause of concern among international health organizations and government agencies such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). The scarcity of the emergence of new antimicrobial agents and the decreasing efficacy of the current antibiotics predominantly cause this crisis. The mechanisms of bacterial resistance are varied and some of them include enzyme inactivation, low-membrane permeability, target site protection or alteration, target overexpression, structural changes of the enzymes or cellular structures, and increased efflux through overexpressed efflux pumps. Due to their distinctive physicochemical characteristics, nanoparticles have become the potentially promising antimicrobial agents that can either work alone or serve as the carriers of antimicrobial agents without necessarily undergoing the standard mechanisms of resistance. Nanoparticle categories, such as metallic, organic, carbon-based, and hybrid systems have proved to be very effective with regard to antibacterial activity against MDR pathogens. Moreover, nanoparticles are under investigation in combination with plant-derived antimicrobials to improve the ability and minimize the toxicity. Recent methods of using nanoparticles are biofilm disruption, quorum sensing, plasmid eradication, efflux pump, and synergist antimicrobial combinations. Irrespective of these improvements, there are safety, biocompatibility, scalability, and environmental impact issues. This review comprises newly developed developments in nanoparticle-based approaches to addressing drug-resistant bacteria and addresses their clinical translation possibilities.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Antimicrobial agents and applications · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Mehrotra R, et al. Effectiveness of existing insomnia therapies for patients undergoing hemodialysis: a randomized clinical trial. Ann Intern Med. 2024;177(2):177–88.10.7326/M23-1794 ↗
2. Ahmed SK, et al. Antimicrobial resistance: Impacts, challenges, and future prospects. J Med Surg Public Health. 2024;2:100081.10.1016/j.glmedi.2024.100081 ↗
3. Manyi-Loh C, et al. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules. 2018;23(4):795.10.3390/molecules23040795 ↗
4. Jhalora V, Bist R. A comprehensive review of molecular mechanisms leading to the emergence of multidrug resistance in bacteria. Indian J Microbiol. 2025;65(2):844–65.10.1007/s12088-024-01384-6 ↗
5. Baciu AP, et al. The burden of antibiotic resistance of the main microorganisms causing infections in humans - review of the literature. J Med Life. 2024;17(3):246–60.10.25122/jml-2023-0404 ↗
6. Founou LL, Founou RC, Essack SY. Antimicrobial resistance in the farm-to-plate continuum: more than a food safety issue. Future Sci OA. 2021;7(5):pFso692.10.2144/fsoa-2020-0189 ↗
7. Abadi A, et al. World health organization report: current crisis of antibiotic resistance. BioNanoSci. 2019;9:778–88.10.1007/s12668-019-00658-4 ↗
8. Haldar J. Confronting the rising threat of antimicrobial resistance: a global health imperative. ACS Infect Dis. 2024;10(1):1–2.10.1021/acsinfecdis.3c00571 ↗
9. Malik B, Bhattacharyya S. Antibiotic drug-resistance as a complex system driven by socio-economic growth and antibiotic misuse. Sci Rep. 2019;9(1):9788.10.1038/s41598-019-46078-y ↗
10. Schillaci D, et al. Pharmaceutical approaches to target antibiotic resistance mechanisms. J Med Chem. 2017;60(20):8268–97.10.1021/acs.jmedchem.7b00215 ↗
11. Brito IL. Examining horizontal gene transfer in microbial communities. Nat Rev Microbiol. 2021;19(7):442–53.10.1038/s41579-021-00534-7 ↗
12. Farhat N, et al. Efflux pumps as interventions to control infection caused by drug-resistance bacteria. Drug Discov Today. 2020;25(12):2307–16.10.1016/j.drudis.2020.09.028 ↗
13. Kaur J, Nobile CJ. Antifungal drug-resistance mechanisms in Candida biofilms. Curr Opin Microbiol. 2023;71:102237.10.1016/j.mib.2022.102237 ↗
14. Malinovská Z, Čonková E, Váczi P. Biofilm formation in medically important Candida species. J Fungi (Basel). 2023;9(10):955.10.3390/jof9100955 ↗
15. Muteeb G, et al. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals (Basel). 2023;16(11):1615.10.3390/ph16111615 ↗
16. Chakravarty B. Genetic mechanisms of antibiotic resistance and virulence in Acinetobacter baumannii: background, challenges and future prospects. Mol Biol Rep. 2020;47(5):4037–46.10.1007/s11033-020-05389-4 ↗
17. Arnold BJ, Huang IT, Hanage WP. Horizontal gene transfer and adaptive evolution in bacteria. Nat Rev Microbiol. 2022;20(4):206–18.10.1038/s41579-021-00650-4 ↗
18. Bassetti M, Giacobbe DR. A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020. Expert Opin Pharmacother. 2020;21(17):2067–71.10.1080/14656566.2020.1802427 ↗
19. Pulingam T, et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2022;170:106103.10.1016/j.ejps.2021.106103 ↗
20. Tang KWK, Millar BC, Moore JE. Antimicrobial Resistance (AMR). Br J Biomed Sci. 2023;80:11387.10.3389/bjbs.2023.11387 ↗
21. Zubair A, et al. Integrative genomic and immunoinformatic approach for characterizing HIV-1 pol, vpr, and Nef genes and designing a multi-epitope vaccine. Sci Rep. 2025;15(1):33690.10.1038/s41598-025-18828-8 ↗
22. Zubair A, et al. Unveiling the dynamics: understanding the current scenario and drivers of HIV epidemiology in Pakistan. Retrovirology. 2025;22(1):12.10.1186/s12977-025-00668-z ↗
23. Zubair A, et al. mRNA vaccines against HIV: Hopes and challenges. HIV Med. 2025;26(6):824–38.10.1111/hiv.70024 ↗
24. Zubair A, Ali M, Akhtar N. HIV-1 Nef Gene characterization and subtype analysis in Pakistan: a molecular docking approach with Mastoparan-L Peptide. International Journal of Peptide Research and Therapeutics. 2025;31(3): 46.10.1007/s10989-025-10702-5 ↗
25. Zubair A, et al. Molecular characterization and drug resistance pattern in pol gene of HIV-1 sub-subtypes circulating in Lahore, Pakistan. Virus Genes. 2025;61(3):324–41.10.1007/s11262-025-02149-z ↗
26. Gow NAR, et al. The importance of antimicrobial resistance in medical mycology. Nat Commun. 2022;13(1):5352.10.1038/s41467-022-32249-5 ↗
27. Pokharel S, Shrestha P, Adhikari B. Antimicrobial use in food animals and human health: time to implement ‘One Health’ approach. Antimicrob Resist Infect Control. 2020;9(1):181.10.1186/s13756-020-00847-x ↗
28. Djordjevic SP, et al. Genomic surveillance for antimicrobial resistance - a One Health perspective. Nat Rev Genet. 2024;25(2):142–57.10.1038/s41576-023-00649-y ↗
29. Streicher LM. Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics. J Glob Antimicrob Resist. 2021;24:285–95.10.1016/j.jgar.2020.12.025 ↗
30. Kirtane AR, et al. Nanotechnology approaches for global infectious diseases. Nat Nanotechnol. 2021;16(4):369–84.10.1038/s41565-021-00866-8 ↗
31. Parmanik A, et al. Current treatment strategies against multidrug-resistant bacteria: a review. Curr Microbiol. 2022;79(12):388.10.1007/s00284-022-03061-7 ↗
32. Weldick PJ, et al. Emerging nanotechnologies for targeting antimicrobial resistance. Nanoscale. 2022;14(11):4018–41.10.1039/D1NR08157H ↗
33. Mba IE, Nweze EI. Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects. World J Microbiol Biotechnol. 2021;37(6):108.10.1007/s11274-021-03070-x ↗
34. Colilla M, Vallet-Regí M. Organically modified mesoporous silica nanoparticles against bacterial resistance. Chem Mater. 2023;35(21):8788–805.10.1021/acs.chemmater.3c02192 ↗
35. Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016;23(9):3319–29.10.1080/10717544.2016.1177136 ↗
36. Lemière J, Carvalho K, Sykes C. Cell-sized liposomes that mimic cell motility and the cell cortex. Methods Cell Biol. 2015;128:271–85.10.1016/bs.mcb.2015.01.013 ↗
37. Shek PN, Yung BY, Stanacev NZ. Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation. Immunology. 1983;49(1):37–44.
38. Bassetti M, et al. Inhaled liposomal antimicrobial delivery in lung infections. Drugs. 2020;80(13):1309–18.10.1007/s40265-020-01359-z ↗
39. Amreddy N, et al. Recent advances in nanoparticle-based cancer drug and gene delivery. Adv Cancer Res. 2018;137:115–70.10.1016/bs.acr.2017.11.003 ↗
40. Sánchez A, Mejía SP, Orozco J. Recent advances in polymeric nanoparticle-encapsulated drugs against intracellular infections. Molecules. 2020;25(16):3760.10.3390/molecules25163760 ↗
41. Ameh T, et al. Silver and copper nanoparticles induce oxidative stress in bacteria and mammalian cells. Nanomaterials (Basel). 2022;12(14):2402.10.3390/nano12142402 ↗
42. Krishnamoorthy R, et al. Antibacterial mechanisms of zinc oxide nanoparticle against bacterial food pathogens resistant to Beta-Lactam antibiotics. Molecules. 2022;27(8):2489.10.3390/molecules27082489 ↗
43. Zafar A, et al. Development and optimization of hybrid polymeric nanoparticles of apigenin: physicochemical characterization, antioxidant activity and cytotoxicity evaluation. Sens (Basel). 2022;22(4):1364.10.3390/s22041364 ↗
44. Elhassan E, et al. Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections. J Control Release. 2022;351:598–622.10.1016/j.jconrel.2022.09.052 ↗
45. Zhang RX, et al. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. Nanoscale. 2017;9(4):1334–55.10.1039/C6NR08486A ↗
46. He X, et al. A Vehicle-free antimicrobial polymer hybrid gold nanoparticle as synergistically therapeutic platforms for staphylococcus aureus infected wound healing. Adv Sci (Weinh). 2022;9(14):e2105223.10.1002/advs.202105223 ↗
47. Jia H, et al. Silver nanoparticles anchored magnetic self-assembled carboxymethyl cellulose-ε-polylysine hybrids with synergetic antibacterial activity for wound infection therapy. Int J Biol Macromol. 2022;210:703–15.10.1016/j.ijbiomac.2022.04.225 ↗
48. Cascioferro S, et al. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections. ChemMedChem. 2021;16(1):65–80.10.1002/cmdc.202000677 ↗
49. Makabenta JMV, et al. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol. 2021;19(1):23–36.10.1038/s41579-020-0420-1 ↗
50. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423–35.10.1038/nrmicro2333 ↗
51. Mamun MM, et al. Nanoantibiotics: functions and properties at the nanoscale to combat antibiotic resistance. Front Chem. 2021;9:687660.10.3389/fchem.2021.687660 ↗
52. Yeh YC, et al. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem. 2020;8:286.10.3389/fchem.2020.00286 ↗
53. Zaidi S, Misba L, Khan AU. Nano-therapeutics: A revolution in infection control in post antibiotic era. Nanomedicine. 2017;13(7):2281–301.10.1016/j.nano.2017.06.015 ↗
54. Chung HS, et al. Rapid beta-lactam-induced lysis requires successful assembly of the cell division machinery. Proc Natl Acad Sci U S A. 2009;106(51):21872–7.10.1073/pnas.0911674106 ↗
55. Zhang YM, Rock CO. Membrane lipid homeostasis in bacteria. Nat Rev Microbiol. 2008;6(3):222–33.10.1038/nrmicro1839 ↗
56. Zhao Y, et al. Small molecule-capped gold nanoparticles as potent antibacterial agents that target Gram-negative bacteria. J Am Chem Soc. 2010;132(35):12349–56.10.1021/ja1028843 ↗
57. Cui Y, et al. The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. Biomaterials. 2012;33(7):2327–33.10.1016/j.biomaterials.2011.11.057 ↗
58. Lemire JA, Harrison JJ, Turner RJ. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat Rev Microbiol. 2013;11(6):371–84.10.1038/nrmicro3028 ↗
59. Kim D, et al. Selective killing of pathogenic bacteria by antimicrobial silver nanoparticle-cell wall binding domain conjugates. ACS Appl Mater Interfaces. 2018;10(16):13317–24.10.1021/acsami.8b00181 ↗
60. Jijie R, et al. Advancements on the molecular design of nanoantibiotics: current level of development and future challenges. Mol Syst Des Eng. 2017;2(4):349–69.10.1039/C7ME00048K ↗
61. Cheeseman S, et al. Antimicrobial metal nanomaterials: from passive to stimuli-activated applications. Adv Sci (Weinh). 2020;7(10):1902913.10.1002/advs.201902913 ↗
62. Hochvaldová L, et al. Antibacterial nanomaterials: Upcoming hope to overcome antibiotic resistance crisis. Nanatechnol Reviews. 2022;11(1):1115–42.10.1515/ntrev-2022-0059 ↗
63. Gupta A, et al. Combatting antibiotic-resistant bacteria using nanomaterials. Chem Soc Rev. 2019;48(2):415–27.10.1039/C7CS00748E ↗
64. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65(13–14):1803–15.10.1016/j.addr.2013.07.011 ↗
65. Muthukrishnan L, Chellappa M, Nanda A. Bio-engineering and cellular imaging of silver nanoparticles as weaponry against multidrug resistant human pathogens. J Photochem Photobiol B. 2019;194:119–27.10.1016/j.jphotobiol.2019.03.021 ↗
66. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomed. 2017;12:1227–49.10.2147/IJN.S121956 ↗
67. Slavin YN, et al. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnol. 2017;15(1):65.10.1186/s12951-017-0308-z ↗
68. Wang X, et al. Chitosan-metal complexes as antimicrobial agent: Synthesis, characterization and Structure-activity study. Polym Bull. 2005;55(1):105–13.10.1007/s00289-005-0414-1 ↗
69. Santos MHdM, et al. Silver nanoparticle–antibiotic combinations: a strategy to overcome bacterial resistance in escherichia coli, salmonella enteritidis and staphylococcus aureus. Antibiotics. 2025;14(10):960.10.3390/antibiotics14100960 ↗
70. Modi SK, et al. Mechanistic insights into nanoparticle surface-bacterial membrane interactions in overcoming antibiotic resistance. Front Microbiol. 2023;14:1135579.10.3389/fmicb.2023.1135579 ↗
71. Natan M, Banin E. From Nano to Micro: using nanotechnology to combat microorganisms and their multidrug resistance. FEMS Microbiol Rev. 2017;41(3):302–22.10.1093/femsre/fux003 ↗
72. Fenoglio I, et al. The oxidation of glutathione by cobalt/tungsten carbide contributes to hard metal-induced oxidative stress. Free Radic Res. 2008;42(8):437–745.10.1080/10715760802350904 ↗
73. Quinteros MA, et al. Oxidative stress generation of silver nanoparticles in three bacterial genera and its relationship with the antimicrobial activity. Toxicol Vitro. 2016;36:216–23.10.1016/j.tiv.2016.08.007 ↗
74. Hailan, W.A., et al., Reactive oxygen species-mediated cytotoxicity in liver carcinoma cells induced by silver nanoparticles biosynthesized using schinus molle extract. Nanomaterials (Basel), 2022;12(1).10.3390/nano12010161 ↗
75. Banerjee S, et al. Oxidative stress, DNA, and membranes targets as modes of antibacterial and antibiofilm activity of facile synthesized biocompatible keratin-copper nanoparticles against multidrug resistant uro-pathogens. World J Microbiol Biotechnol. 2022;38(2):20.10.1007/s11274-021-03187-z ↗
76. Shamaila S, et al. Gold Nanoparticles: An efficient antimicrobial agent against enteric bacterial human pathogen. Nanomaterials (Basel). 2016;6(4):71.10.3390/nano6040071 ↗
77. Chatterjee AK, Chakraborty R, Basu T. Mechanism of antibacterial activity of copper nanoparticles. Nanotechnology. 2014;25(13):135101.10.1088/0957-4484/25/13/135101 ↗
78. Sutherland IW. The biofilm matrix–an immobilized but dynamic microbial environment. Trends Microbiol. 2001;9(5):222–7.10.1016/S0966-842X(01)02012-1 ↗
79. Hosnedlova B, et al. Effect of biosynthesized silver nanoparticles on bacterial biofilm changes in S. aureus and E. coli. Nanomaterials. 2022;12(13):2183.10.3390/nano12132183 ↗
80. Brown AN, et al. Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol. 2012;78(8):2768–74.10.1128/AEM.06513-11 ↗
81. Li CH, et al. Phytochemical-based nanocomposites for the treatment of bacterial biofilms. ACS Infect Dis. 2019;5(9):1590–6.10.1021/acsinfecdis.9b00134 ↗
82. Abo-Shama UH, et al. Synergistic and antagonistic effects of metal nanoparticles in combination with antibiotics against some reference strains of pathogenic microorganisms. Infect Drug Resist. 2020;13:351–62.10.2147/IDR.S234425 ↗
83. Bera S, Mondal D. Drug targeting and stimuli sensitive drug delivery systems. Norwich, NY, USA: William Andrew Publishing. 2018.
84. Abdelghany SM, et al. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomed. 2012;7:4053–63.
85. Li P et al. Synergistic antibacterial effects ofβ-lactam antibiotic combined with silver nanoparticles. Nanotechnology. 2005;16(9):1912.10.1088/0957-4484/16/9/082 ↗
86. Chamundeeswari M, et al. Preparation, characterization and evaluation of a biopolymeric gold nanocomposite with antimicrobial activity. Biotechnol Appl Biochem. 2010;55(1):29–35.10.1042/BA20090198 ↗
87. Hazime N et al. Enhancing colistin activity against colistin-resistant escherichia coli through combination with alginate nanoparticles and small molecules. Pharmaceuticals (Basel), 2022;15(6).10.3390/ph15060682 ↗
88. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004;275(1):177–82.10.1016/j.jcis.2004.02.012 ↗
89. Rosi NL, Mirkin CA. Nanostructures biodiagnostics Chem Rev. 2005;105(4):1547–62.
90. Lee N-Y, Ko W-C, Hsueh P-R. Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. Front Pharmacol. 2019;10:1153.10.3389/fphar.2019.01153 ↗
91. Nel AE, et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater. 2009;8(7):543–57.10.1038/nmat2442 ↗
92. Aljuffali IA, Huang CH, Fang JY. Nanomedical strategies for targeting skin microbiomes. Curr Drug Metab. 2015;16(4):255–71.10.2174/1389200216666150812124923 ↗
93. Morones JR, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16(10):2346–53.10.1088/0957-4484/16/10/059 ↗
94. Hoshyar N, et al. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomed (Lond). 2016;11(6):673–92.10.2217/nnm.16.5 ↗
95. Mahmoudi M, et al. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev. 2011;111(9):5610–37.10.1021/cr100440g ↗
96. Zazo H, Colino CI, Lanao JM. Current applications of nanoparticles in infectious diseases. J Control Release. 2016;224:86–102.10.1016/j.jconrel.2016.01.008 ↗
97. Daima HK, Bansal V. Influence of physicochemical properties of nanomaterials on their antibacterial applications. Nanotechnology in diagnosis, treatment and prophylaxis of infectious diseases. Elsevier; 2015. pp. 151–66.10.1016/B978-0-12-801317-5.00010-4 ↗
98. Hamouda T, Baker JR Jr. Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. J Appl Microbiol. 2000;89(3):397–403.10.1046/j.1365-2672.2000.01127.x ↗
99. Railsback JG, et al. Weakly charged cationic nanoparticles induce DNA bending and strand separation. Adv Mater. 2012;24(31):4261–5.10.1002/adma.201104891 ↗
100. Rai MK, et al. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol. 2012;112(5):841–52.10.1111/j.1365-2672.2012.05253.x ↗